Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 9;10(10):1415-1422.
doi: 10.1021/acsmedchemlett.9b00193. eCollection 2019 Oct 10.

Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase

Affiliations

Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase

Shweta Sinha et al. ACS Med Chem Lett. .

Abstract

A hybrid pharmacophore approach is used to design and synthesize novel chalcone-thiazole hybrid molecules. Herein, thiazole has been hybridized with chalcone to obtain a new class of 5-LOX inhibitors. In vitro biological evaluation showed that most of the compounds were better 5-LOX inhibitors than the positive control, Zileuton (IC50 = 1.05 ± 0.03 μM). The best compounds in the series, namely, 4k, 4n, and 4v (4k: IC50 = 0.07 ± 0.02 μM, 4n: IC50 = 0.08 ± 0.05 μM, 4v: 0.12 ± 0.04 μM) are found to be 10 times more active than previously reported 2-amino thiazole (2m: IC50 = 0.9 ± 0.1 μM) by us. Further, 4k has redox (noncompetitive) while 4n and 4v act through a competitive inhibition mechanism. SAR indicated that the presence of methoxy/methyl either in the vicinity of chalcone or both thiazole and chalcone contributed to the synergistic inhibitory effect.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Design of chalcone–thiazole hybrids via molecular hybridization.
Figure 2
Figure 2
Structures of reported 5-LOX inhibitors.
Figure 3
Figure 3
(a) Pharmacophoric model (Ph model) generated from known 5-LOX inhibitors in software MOE 2016.0801; (b) Ph model with geometric distances (A0) in a 3D spatial relationship; pharmacophore mapping of (c) 4k and (d) 4n with a Ph model. Pharmacophoric features: Hydrophobic (Hyd - green), H-bond acceptor (Acc2 - orange) and (blue in (Figure 3a)). Inhibitors superimposed in (Figure 3a) are Zileuton - magenta, Atreleuton - navy blue, Siteleuton - brown, di-o-prenylated - pink, and diarylsulfonylurea chalcone - black.
Scheme 1
Scheme 1. Synthesis of Chalcone-Thiazole Hybrid (4aw) Derivatives
Figure 4
Figure 4
Lineweaver–Burk plots for inhibitors at 0, 2, and 5 μM concentrations: (a) 4k, (b) 4n, (c) 4v. [S] = concentration of the substrate (AA, in μM), V = reaction rate.
Figure 5
Figure 5
Pseudoperoxidase activity plots for the consumption of 13(S)-HpODE (at 234 nm; control subtracted) by (a) Zileuton, (b) 4k, (c) 4n, (d) 4v, (e) 4b, (f) 4h, (g) 4m, (h) 4f, and (i) 4p as a function of time (in sec).
Figure 6
Figure 6
Binding modes of compounds with amino acid residues of 5-LOX (pdb ID 3O8Y). (a) Ligplot interaction of 4n. (b) Docked pose of 4n. (c) Ligplot interaction of 4v. (d) Docked pose of 4v. Dotted lines indicate interactions. Colors depicted are hydrogen: cyan, carbon: gray, nitrogen: blue, oxygen: red, sulfur: yellow.

References

    1. Haeggström J. Z.; Rinaldo-Matthis A.; Wheelock C. E.; Wetterholm A. Advances in eicosanoid research, novel therapeutic implications. Biochem. Biophys. Res. Commun. 2010, 396, 135–139. 10.1016/j.bbrc.2010.03.140. - DOI - PubMed
    1. Werz O.; Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol. Ther. 2006, 112, 701–718. 10.1016/j.pharmthera.2006.05.009. - DOI - PubMed
    1. De Souza M. V. N. Synthesis and biological activity of natural thiazoles: An important class of heterocyclic compounds. J. Sulfur Chem. 2005, 26, 429–449. 10.1080/17415990500322792. - DOI
    1. Chhabria M. T.; Patel S.; Modi P.; Brahmkshatriya P. S. Thiazole: A Review on Chemistry, Synthesis and Therapeutic Importance of its Derivatives. Curr. Top. Med. Chem. 2016, 16 (26), 2841–2862. 10.2174/1568026616666160506130731. - DOI - PubMed
    1. Liaras K.; Fesatidou M.; Geronikaki A. Thiazoles and Thiazolidinones as COX/LOX Inhibitors. Molecules 2018, 23, 685–706. 10.3390/molecules23030685. - DOI - PMC - PubMed

LinkOut - more resources